The point of no re­turn for Mer­ri­mack? Can­cer drug de­vel­op­er ax­es yet an­oth­er drug and more staff

Mer­ri­mack just can’t catch a break.

On Thurs­day, the com­pa­ny said it was aban­don­ing its ex­per­i­men­tal drug, MM-310, af­ter an ear­ly-stage study in­volv­ing pa­tients with sol­id tu­mors showed that treat­ment with the drug was cu­mu­la­tive­ly tox­ic to pa­tients, de­spite tri­al pro­to­col amend­ments.

As a re­sult, the com­pa­ny said it was cut­ting jobs, but did not spec­i­fy how many. It now has two pre­clin­i­cal drugs — MM-401 and MM-201 — left in its ar­se­nal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER